Lupin Limited - India's Leading Pharma Company |
ICMR HOME | Case Studies Collection Please note: This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source. |
||||||||||
"Lupin Laboratories is undergoing an aggressive restructuring exercise, which will sharpen its strategic focus, improve the financial structure and reposition it as one of the leading players in the Indian pharmaceutical industry."1 - Kavita Gupta, Director, Corporate Development, Lupin Limited in November 1999. IntroductionIn April 2004, Lupin Limited (Lupin) became the first Indian pharmaceutical company to receive an ANDA2 approval for Cefixime3. The company subsequently launched its first branded product - anti-infective Suprax (Cefixime Oral Suspension) in the US.
Founded in 1968 with an initial capital of just Rs. 5000, Lupin witnessed significant growth to become a large, Rs 3 billion plus organization in the early 1990s. The company had grown at an average annual growth rate of 40% since its inception, twice as fast as the growth of the Indian pharmaceutical industry.
Lupin Limited - India's Leading Pharma Company - Next Page>>
1] Datta, Anirudha, Rastogi, Atul, "Winds of Change at Lupin Labs," www.indiainfoline.com, November 18, 1999.
|
Case Studies Links:-
Case Studies,
Short Case Studies,
Simplified Case Studies. |